证券日报网讯 1月26日，九安医疗发布公告称，公司预计2025年度归属于上市公司股东的净利润为 202，000万元至235，000万元，比上年同期166，872.73万元增长21.05%至40.83%。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Dongxing Medical (301290) reported a total of 8,993 shareholders as of January 20, 2026, including credit accounts [1]

Report Summary 1. Report Industry Investment Rating - Not provided in the content 2. Core View of the Report - The company achieved a significant turnaround in net profit and net profit after non-recurring items in 2025 compared to 2024, mainly due to increased international market expansion, a product differentiation strategy, cost reduction and efficiency improvement measures, and refined management [22]. - The company's performance improvement in 2025 is mainly based on its long - term product and manufacturing technology accumulation, enhanced overall solution capabilities and globalization service capabilities, as well as timely strategic adjustments in 2024 [23]. 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - Research object: Chutian Technology [17] - Industry: Medical devices [17] - Reception time: 2026 - 01 - 26 [17] - Listed company reception staff: Board Secretary Huang Yuting, Securities Affairs Representative Zhou Dewei [17] 3.2 Detailed Research Institutions - Reception object type: Securities company - Institution: China Merchants Securities - Number of related personnel: 2 [20] 3.3 Research Institution Proportion - Not detailed in the content 3.4 Main Content Data 3.4.1 Reasons for the Company's Profit Improvement in 2025 - Increased international market expansion: In 2025, overseas business entered a rapid growth channel, with breakthroughs in Southeast Asia, the Middle East and Africa, and the Americas. The proportion of international business in the company's overall business increased significantly, driving profit growth [22]. - Product differentiation and cost - reduction: Since the second half of 2024, the company adopted a product differentiation strategy to improve order quality and carried out a series of cost - reduction and efficiency - improvement measures, which significantly increased the gross profit margin [22]. - Refined management: Since the second half of 2024, the company carried out refined management measures, and the overall operating cost in 2025 was effectively controlled, with a significant decrease in total period expenses compared to the same period in 2024 [22]. 3.4.2 Industry Trends - Domestic industry competition is still fierce but gradually easing, with characteristics such as accelerated domestic substitution, increased market concentration, expanded advantages of leading enterprises, and international market expansion becoming a new growth point [23]. - The focus of industry competition has shifted from traditional equipment performance to technological integration, system solutions, and global service capabilities [23]. 3.4.3 Overseas Export in 2025 - The company's international sales and service system team has been growing, with local sales and service outlets established in more than 20 key countries and regions. It focuses on five major regions and promotes high - quality sales and services [23]. - The export orders in 2025 increased compared to 2024 [23]. 3.4.4 Pharmaceutical Robot Layout - The company's pharmaceutical robot business layout focuses on the core pharmaceutical equipment industry chain and the medical clean core sector, aiming to upgrade pharmaceutical equipment to unmanned and intelligent levels [23]. - The company has achieved self - production and product implementation of clean robots and sorting robots, which can effectively meet the needs of existing business scenarios [24]. - The core competitive advantages are a deep understanding of application scenarios and downstream pharmaceutical production processes, which can help product iteration and efficiency improvement [24]. 3.4.5 Operating Conditions of ROMACO - ROMACO Group's operating conditions have improved steadily compared to 2024, and its core business indicators and market competitiveness have increased [24]. - Whether goodwill will be impaired and the impairment amount need to be based on formal reports from third - party asset appraisal companies and audit institutions [24]. 3.4.6 New Product Development - The company has been insisting on technological innovation, with a high R & D investment proportion in the industry. It has continuously launched new products and technologies in recent years [25]. - Future products include continuous BFS, fully automatic intelligent lamp inspection machines, etc. The company will continue to implement the "dual - priority" strategy of product and manufacturing technology [25]. 3.4.7 Business Outlook in 2026 - In the business aspect, the company will continue to expand overseas markets, promote the globalization strategy, and increase the proportion of international business in revenue. It will also focus on innovation to drive the integration of the pharmaceutical equipment industry chain with the international market [25]. - In the management aspect, the company will continue to implement "quality improvement and efficiency enhancement", using technological means and management measures to achieve cost reduction and efficiency improvement [25].

本报告期内，公司净利润较去年同期实现增长，主要源于资管业务在大类资产配置方面表现良好。公司 始终致力于实现资产保值增值，并持续提升风险抵御能力。此外，公司试剂盒类产品作为常规家用上呼 吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 格隆汇1月26日丨九安医疗(002432.SZ)公布，预计2025年归属于上市公司股东的净利润202,000万元～ 235,000万元，比上年同期增长21.05%～40.83%，扣除非经常性损益后的净利润207,000万元～240,000万 元，比上年同期增长23.18%～42.81%。 ...

肺癌一直是中国癌症中发病率和死亡率最高的病种。绝大部分肺癌早期表现形式是肺部小结节。中国患 有肺结节人数约为1.5亿人，超过95%的肺结节为良性。目前，针对肺结节和肺癌的检测诊断技术包括 CT等影像技术、痰细胞学、传统抗原类肿瘤标志物等。但这些诊断技术要么检测率低，要么无法作为 早期诊断筛查手段。 胡海以低剂量螺旋CT（LDCT）为例介绍道，LDCT已成为肺癌高危人群（如吸烟者、有家族病史者） 的常用筛查手段，能准确筛查出肺部结节存在，但LDCT难以区分小结节良恶性，常规做法是让患者定 期随访检查，但实际随访依从率较低，导致很多早期病灶错失干预时机。 "解决肺结节良恶性鉴别诊断，是突破肺癌早诊难题，降低肺癌死亡率的关键。"胡海说道。 1月26日，记者从中国科学院杭州医学研究所获悉，该所研究员、该所附属肿瘤医院学术副院长胡海科 研团队主导研发的十三种肺癌相关抗体检测试剂盒（流式荧光免疫法），正式获得国家药监局三类医疗 器械注册证，成为全球首个针对CT发现肺结节（尤其是小结节）良恶性鉴别的辅助诊断试剂盒，并有 望显著提升肺癌早期诊断率。 团队从2016年起聚焦肺癌早诊痛点，并锁定肿瘤自身抗体检测技术。胡海介绍，人 ...

截至本公告日期，IberisRDN系统是全球唯一获准使用经桡动脉方法(TRA)和经股动脉入路方法(TFA)的 肾神经阻断(RDN)产品。TRA使RDN更安全、更有效、更便宜。集团的最终目标是为全球患者提供门诊 RDN手术。安通已于2016年于欧洲取得IberisRDN系统的CE标志。 安通与柏盛就IberisRDN系统的商业化达成战略伙伴关系，相关合作涵盖多个地区，包括但不限于欧盟 国家、亚太地区及拉丁美洲(LATAM)地区。 智通财经APP讯，百心安-B(02185)发布公告，最近，本公司附属公司上海安通医疗科技有限公司(安通) 研发的Iberis多极肾动脉射频消融导管系统(Iberis RDN系统)已在印度尼西亚注册。该注册得到柏盛国际 集团有限公司(柏盛)及安通的共同支持。 ...

大博医疗表示，报告期内，公司聚焦主业，坚持产品创新、技术服务、国际化发展战略，推动各项业务 持续稳定健康发展。 北京商报讯（记者 丁宁）1月26日晚间，大博医疗（002901）发布2025年业绩预告显示，预计2025年归 属净利润为5.8亿元至6.1亿元，同比增长62.55%–70.96%。 ...

中证智能财讯迈得医疗（688310）1月26日晚间披露2025年度业绩预告，预计2025年归母净利润6652.13万元，上年同期亏损1998.12万元；扣非净利润预计 5463.95万元，上年同期亏损2628.09万元。以1月26日收盘价计算，迈得医疗目前市盈率（TTM）约为40.63倍，市净率（LF）约3.35倍，市销率（TTM）约 9.66倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 200 @ 20 100 300 50 47624 40919 To83 29877 32x43 29.54 224 0 -50 -100 -150 2022-06-30 2021-12-37 2021-06-30 ' 2020-12-37 2022-12-37 <3-12-37 3-06-30 2n. -○- 公司 -○- 行业均值 100 ହ 90 80 70 63 69 60 50 (8 40 30 2 20 15086 15 10 AR 0 2027-12-37 | 2022-72-37 1 2020-12-37 1 2021-06-30 ' 023-12-37 ...

Core Viewpoint - The company is actively expanding its global presence and enhancing local service capabilities to strengthen its competitive advantage in the high-end medical device market, primarily driven by demand from Western developed countries [2] Group 1: Market Position - Western developed countries remain the primary source of revenue for high-end medical device products and brands [2] - The company is focusing on building a localized service capability to better meet customer needs [2] Group 2: Strategic Initiatives - The company is advancing its global layout to enhance supply chain resilience [2] - The expansion plan in Europe is progressing in an orderly manner [2]

证券日报网讯 1月26日，翔宇医疗在互动平台回答投资者提问时表示，目前公司聚焦非侵入式康复全场 景布局，同时已启动侵入式领域的探索，与西安交大共建的康复器械实验室已开展侵入式相关实验，将 重点关注与公司现有渠道、市场应用范围高度契合的侵入式/半侵入式技术方向。公司将依据临床效果 验证，优先选择落地速度快、患者接受度高的细分方向。 （文章来源：证券日报） ...